Imagyn Medical Technologies Inc.

Device companies large and small have failed repeatedly in efforts to address bifurcations, which remain one of the largest unmet opportunities in cardiology. Cappella thinks it can solve the problem

Labcoat has modified inkjet printing technology to do what big companies haven't: create a method for making safer and more effective drug-eluting stents with less drug and polymer. By Stephen Levin D

Once heralded as a promising device market, women's health has bedeviled a host of start-ups. Here's how one company beat the odds. by Stephen Levin For many years, women were forced to take a backsea

With venture capital firms increasingly interested only in device start-ups aimed at hundred-million-dollar or more markets, finding backers for new technologies with smaller applications is almost im